Acyclic pyrazolo[3,4-d]pyrimidine nucleoside as potential leishmaniostatic agent by Hasan, A. et al.
  
PLEASE SCROLL DOWN FOR ARTICLE
This article was downloaded by:
On: 17 January 2011
Access details: Access Details: Free Access
Publisher Taylor & Francis
Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-
41 Mortimer Street, London W1T 3JH, UK
Nucleosides, Nucleotides and Nucleic Acids
Publication details, including instructions for authors and subscription information:
http://www.informaworld.com/smpp/title~content=t713597286
Acyclic Pyrazolo[3,4-d]Pyrimidine Nucleoside as Potential
Leishmaniostatic Agent
A. Hasana; M. Satyanarayanaa; A. Mishraa; D. S. Bhakunia; Ram Pratapa; A. Dubeb; P. Y. Gurub
a Division of Medicinal & Process Chemistry, Central Drug Research Institute, Lucknow, India b
Division of Parasitology, Central Drug Research Institute, Lucknow, India
To cite this Article Hasan, A. , Satyanarayana, M. , Mishra, A. , Bhakuni, D. S. , Pratap, Ram , Dube, A. and Guru, P.
Y.(2006) 'Acyclic Pyrazolo[3,4-d]Pyrimidine Nucleoside as Potential Leishmaniostatic Agent', Nucleosides, Nucleotides
and Nucleic Acids, 25: 1, 55 — 60
To link to this Article: DOI: 10.1081/15257770500379017
URL: http://dx.doi.org/10.1081/15257770500379017
Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf
This article may be used for research, teaching and private study purposes. Any substantial or
systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or
distribution in any form to anyone is expressly forbidden.
The publisher does not give any warranty express or implied or make any representation that the contents
will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses
should be independently verified with primary sources. The publisher shall not be liable for any loss,
actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly
or indirectly in connection with or arising out of the use of this material.
Nucleosides, Nucleotides, and Nucleic Acids, 25:55–60, 2006
Copyright C© Taylor & Francis Group, LLC
ISSN: 1525-7770 print / 1532-2335 online
DOI: 10.1081/15257770500379017
ACYCLIC PYRAZOLO[3,4-d]PYRIMIDINE NUCLEOSIDE
AS POTENTIAL LEISHMANIOSTATIC AGENT∗
A. Hasan, M. Satyanarayana, A. Mishra, D. S. Bhakuni, and Ram Pratap
 Division of Medicinal & Process Chemistry, Central Drug Research Institute,
Lucknow, India
A. Dube and P. Y. Guru  Division of Parasitology, Central Drug Research Institute,
Lucknow, India
 A new synthesis of 6-amino-1-hydroxyethoxymethyl-4 (5H)-oxopyrazolo[3,4-d]pyrimidine (4) has
been mentioned. Compound 4 exhibited inhibition of amastigotes of Leishmania donovani to the
extent of 89% at 30 µg/mL, whereas iso-guanine analogue 5 had the inhibition only to the extent of
52.8% at 100 µg/mL in vitro. In hamster model the maximum inhibitory response for compound 4
against amastigotes multiplication was observed to be 94% at 50 mg/kg single dose for 5 consecutive
days.
Keywords Leishmania donovani; Amastigotes; Promastigotes; Hamster; Leishmanio-
static; Pyrazolo[3,4-d]pyrimidine
INTRODUCTION
The hemoflagellates of the genera leishmania infect nearly 40 million
people every year in tropical and subtropical parts of the world due to
lack of satisfactory curative and preventive chemotherapeutic agents.[1]
The biochemical targets being pursued for design of suitable chemother-
apeutic agents include inhibitors of purine salvage pathways,[2] DNA-
gyrase,[3] tubulin binding,[4] hydroperoxide metabolism,[5] and trypan-
othione reductase.[6] The parasite has evolved a unique mechanism for
scavenging purines and their nucleotides from the host in absence of
its de-novo synthesis. In the process, nucleotides are dephosphorylated
to nucleosides prior to the cell entry. Two scavenging channels have
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been identified on parasite cell surface.[7] One transports inosine, guano-
sine, and their analogues while the second carries adenosine and thymi-
dine analogues. The promastigotes utilizing first channel concentrate on
4-hydroxypyrazolo[3,4-d]pyrimidine (HPP, 1) assuming to be hypoxanthine
from culture medium and process it to 4-amino-pyrazolo[3,4-d]pyrimidine-
l-ribofuranosyl-5′-monophosphate (4-APRP-MP), which ultimately becomes
lethal to the parasite. The HPP, however, is not metabolized to the corre-
sponding guanosine stage (2) and, in fact, direct administration of 6-amino-4-
hydroxy-pyrazolo[3,4-d]pyrimidine-riboside (2) did not inhibit the parasite
proliferation,[8] whereas 3-deaza guanosine[9] (3), which is 20 times more
active than 4-hydroxy-pyrazolo[3,4-d]pyrimidine (1, allopurinol), did. The
difference in activity profile of guanosine analogues 2 and 3 suggests the
strict stereospecificity requirement of salvage enzyme. The synthesis of 3 is,
however, cumbersome, which prompted us to search for simpler analogues.
Acyclic sugars are known to mimic the ribose portion of nucleosides,[10]
which led us to prepare the analogue 4 for antileishmanial activity. The
iso-guanine analogue 5 was also prepared for structure activity relationship
study.
SCHEME 1
Compound 4 has been previously synthesized[11] by Beauchamp
et al. for antiviral screening by condensation of polyacetylated
6-amino-4-hydroxy-pyrazolo[3,4-d]pyrimidine base with suitably pro-
tected glycone. Here we report another synthesis by simple condensation
of 4,6-dimethylthiopyrazolo[3,4-d]pyrimidine with l-chloromethyl-2-
benzoyloxyethane in a regiospecific manner to provide 4,6-dimethylthio-
l-(benzoyloxyethoxymethyl)-pyrazolo[3,4-d]pyrimidine, which on treat-
ment with methanolic ammonia at ambient temperature afforded
4,6-dimethylthio-l-hydroxyethoxymethyl-pyrazolo[3,4-d]pyrimidine (6).[12]
Compound 6 on heating with sodium hydroxide in dioxan yielded
6-methylthio-4(5H)-oxo-l-hydroxyethoxymethyl-pyrazolo[3,4-d]pyrimidine
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SCHEME 2 Reagents and conditions: (i) Aq. NaOH, Dioxan (ii) Ethanolic NH3.
(7) after selective substitution of 4-methylthio group. The substitution of
6-methylthio group with ethanolic ammonia at 160◦C gave 6-amino-4(5H)-
oxo-l-hydroxyethoxymethyl-pyrazolo[3,4-d]pyrimidine (4) in good yield.
For the synthesis of iso-guanine analogue 5, compound 6 was converted
to 4-acetylamino-6-methylsulphonyl-1-acetoxymethyl-pyrazolo[3,4-d]pyrimi-
dine (8) according to our earlier procedure,[12] which on treatment with 2N
sodium hydroxide solution afforded the required product 4-amino-6(7H)-
oxo-1-hydroxyethoxymethyl-pyrazolo[3,4-d]pyrimidine (5).
BIOLOGICAL SCREENING
The method used for assessing in-vitro anti-leishmanial activity was sim-
ilar to that used by Bhatnagar et al.,[13] except that in this case peri-
toneal macrophages of BALB/C mice infected with L. donovani (Dd8 strain)
amastigotes were used. However, the rest of the procedures were similar. The
percentage inhibition of amastigotes is calculated by using average number
of amastigotes per macrophage in treated (PT) and in control (PC) with
formula [% inhibition = 100 − (PT × 100)/PC]. Anti-leishmanial activity
in vivo against amastigotes of L. donovani was determined in hamsters with
Dd8 strain. Male hamsters weighing 35–40 grams were infected with 1 × 107
amastigotes, and 4 weeks later the intensity of infection was assessed by spleen
biopsy. Animals with 2+ infection having a count of 11–50 amastigotes per
D
o
w
n
lo
ad
ed
 A
t:
 0
5:
13
 1
7 
Ja
nu
ar
y 
20
11
58 A. Hasan et al.
100 spleen cell nuclei were chosen for screening compounds. Usually 2–3
animals were used for each dose schedule of the test compound as well as
standard anti-leishmanial drug, i.e., sodium stibogluconate (SSG), while 2–3
untreated animals were kept as controls. The test animals were treated with
a single daily intraperitonial injection of the compound and SSG for 5 days.
The drug suspension employed for the test was prepared by grinding accu-
rately weighed drug in distilled water (2–5 mL) with 1–2 drops of tween-80.
This stock solution was suitably diluted for use. The post treatment biopsy
was conducted one week after the last day of the drug administration. In-
tensity of infection in treated animals was compared with that of the control
animals and percentage inhibition was calculated using a formula, i.e., %
inhibition = 100 − (actual no. of amastigotes in treatment × 100)/(initial
no. of amastigotes in treatment × increase in untreated control). A dose–
response test was carried out by treating groups of infected hamsters with
different doses for 5 consecutive days.
RESULTS AND DISCUSSION
Compound 4 showed marked inhibitory activity of amastigotes in vitro
to the extent of 89% at 30 [µ]g/mL, whereas 5 had the inhibition only to
52.8% at 100 [µ]g/mL. Because of the high order of activity of compound 4,
it was tested in vivo in hamster against amastigotes of L. donovani. It showed
a strong inhibitory effect, which was reproducible as indicated in replicate
experiments, and the results are given in Table 1. The maximum response
was obtained at day 7 post-treatment when treated at 25 mg/kg dose ad-
ministered daily for five consecutive days; however, there was no complete
inhibition even after post-treatment day 28 and also after increasing the dose
level. The above study suggests that the compound does not free infected
hamsters from parasites even after treatment at high doses. The compound
only reduces the parasite load up to 94%, which therefore suggests that com-
pound 4 has a leishmaniostatic effect and can be more effective only if used
in combination with some other drugs. However, the activity of compound 4
TABLE 1 In vivo Anti-Leishmanial Activity of Compound 4 against L. donovani Amastigotes in Hamster
% Inhibition
S. No Dose (mg/kg∗5 days) on 7th day
1 5 64.2 ± 5
2 10 84 ± 6.25
3 25 92.5 ± 12.5
4 25 74.3 ± 6.5 (on 28th day)
5 50 94 ± 16.4
6 100 Death
Sodium stibogluconate
7 25 86.8 ± 2.4
8 50 90.4 ± 2.8
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is comparable with the standard drug, sodium stibogluconate. This study at
least finds a simple guanosine analogue of pyrazolo[3,4-d]pyrimidine series
to have strong leishmaniostatic activity.
EXPERIMENTAL PROCEDURE
Melting points were taken with Buchi capillary apparatus (silicon bath)
and are uncorrected. UV spectra were recorded on a Perkin-Elmer-202 spec-
trophotometer (v max in nm), IR spectra on a Perkin-Elmer-157 grating in-
fracord (v max in cm−1), and PMR spectra on a Perkin-Elmer-360L, 60 MHz
(chemical shift in δ scale). The mass spectra were recorded on a JEOL-D-300
spectrophotometer. The compounds were routinely checked for purity on
silica gel plates and spots were located under UV lamp/spraying with 100%
sulphuric acid in ethanol followed by heating at 100◦C. Evaporations were
carried out at <30◦C under reduced pressure.
1-(Hydroxyethylmethyl)-6-methylthio-4(5H)-oxopyrazolo[3,4-d]pyrimi-
dine (7). A mixture of 6 (1.3 g, 4.5 mmol), dioxan (35 mL), and 2N
sodium hydroxide was refluxed for 6 h. The resulting mixture was cooled,
neutralized with 2N hydrochloric acid, and concentrated under reduced
pressure. The residue was chromatographed on silica gel column. Elution
with chloroform methanol (3%) afforded 7 (1 g, 85%); m.p: 172◦C; MS
(m/z): 256 (m+); PMR (CDCl3 + DMSO-d6): 7.80 (s, 1H, H-3), 5.53 (s,
2H, H-1′), 3.55 (bs, 4H, H-3′ & H-4′), 2.5 (s, 3H, SCH3). Anal. Calcd. For
C9H12N4O3S (C, 42.2 H, 4.7; N, 21.9. Found: C, 42.6; H, 4.9; N, 22.2%.
6-Amino-1-hydroxyethoxymethyl-4(5H)-oxopyrazolo[3,4-d]pyrimidine
(4). A mixture of 7 (0.5 g, 2 mmol) and ethanolic ammonia (60 mL
ethanol, saturated with ammonia at 0◦C) was heated in a steel bomb at 160◦C
for 3 days. Ethanol and excess of ammonia were removed under reduced
pressure. The product was crystallized from ethanol to give 4 (0.23 g, 57%);
mp: 248–250◦C (de) [Lit.11 mp 250–253◦C]; IR (KBr): 1675 (CO); 5.40 (s,
2H, H-1′), 5.1–4.5 (m, 1H, NH) 3.50 (bs, 4H, H-3′ & H-4′). Anal.Calcd for
C8H11N5O3.H2O: C, 39.5; H, 5.4; N, 28.8 Found: C, 39.9; H, 5.3; N, 28.9%.
4-Amino-6(7H)-oxo-1-hydroxyethoxymethyl-pyrazolo[3,4-d]pyrimidine
(5). A mixture of 8 (2.0 g, 5 mmol) and 2N sodium hydroxide solution
(40 mL) was stirred at 65◦C for 3 h. The resulting mixture was extracted
with ethyl acetate. The organic layer was separated, washed with water, dried
(Na2SO4), and concentrated in vacuo. The crude product thus obtained was
chromatographed over silica gel column. Elution of the column with CHCl3:
MeOH: CH3COCH3 (88:10:2, V/V) gave 5 (0.5 g, 45%); mp: 234–235◦C;
MS (m/z): 226 (m+1); PMR (DMSO-d6): 8.4 (s, 1H, H-3), 7.4 (bs, 3H, NH
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and NH2), 5.9 (s, 2H, H-1), 4.8–4.5 (m, 4H, H-2 & H-3). Anal. Calcd. for
C8H11N5O3: (C, 42.7; H, 4.8; N, 31.1. Found: C, 42.8; H, 4.8; N, 31.0%.
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